Navigation Links
CSL Behring Announces First Patient Treated in Phase III Study of Fibrinogen Concentrate (Human)(FCH) to Control Bleeding During Aortic Aneurysm Surgery
Date:3/15/2012

HELSINKI, Finland, March 15, 2012 /PRNewswire/ -- CSL Behring announced today that the first patient has been treated as part of the REPLACE Phase III clinical trial evaluating the efficacy and safety of fibrinogen concentrate (Human) (FCH) in controlling microvascular bleeding during aortic aneurysm surgery.

The purpose of this study is to demonstrate that Fibrinogen Concentrate (Human)(FCH) can reduce intraoperative bleeding and, therefore, the volume of donor blood products (e.g., fresh frozen plasma, platelets, and red blood cells) needed during complex cardiovascular surgical procedures such as aortic aneurysm surgery. The study will also aim to show that FCH is safe and well tolerated. The primary efficacy endpoint measurement will be the number of units of all allogeneic blood products transfused during the first 24 hours after administration of FCH or placebo. 

"Potentially life-threatening bleeding events can occur during cardiovascular surgery because the patient's fibrinogen levels are depleted, which delays clotting," said Dr. Niels Rahe-Meyer, Department of Anesthesiology and Intensive Care, Franziskus Hospital, Bielefeld, Germany and coordinating investigator  of the study. "The REPLACE Phase III study will help determine if FCH treatment can safely reduce the number of transfusions needed during cardiovascular surgery. If this is the case, we will have a powerful new option for use in protecting cardiovascular surgery patients from potentially life-threatening bleeding and transfusion-associated adverse events and discomfort." 

Of the 12 million units of blood used in the United States each year, 15 percent are used in cardiovascular surgery. Studies have shown that blood transfusion during or after adult cardiac surgery is associated with increased long-term mortality.

"As a global leader in the development of plasma-derived and recombinant coagulation fact
'/>"/>

SOURCE CSL Behring
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. CSL Behring Recognized as a "Pioneer" By European Organisation for Rare Diseases (EURORDIS)
2. First Patient Screened in CSL Behring Global Phase I/III Study of Recombinant Single-Chain Factor VIII
3. CSL Behring Receives FDA Orphan Drug Designation for rVIIa-FP, a Novel Therapy in Development to Treat Hemophilia A and Hemophilia B Patients Who Have Inhibitors
4. CSL Behring Receives FDA Approval of Expanded Label on Berinert® for Self-administration and Treatment of Acute Laryngeal Attacks of Hereditary Angioedema
5. CSL Behring Seeks Proposals for Interlaken Leadership Awards, Supporting Innovative Research Into Neuroimmunology
6. CSL Behring Receives EU Orphan Drug Designations for rVIIa-FP for Hemophilia A and B Treatment
7. National Organization for Rare Disorders Presents CSL Behring With 2011 Corporate Award
8. CSL Behring Marks World Hemophilia Day with Coagulation Factor Donation to World Federation of Hemophilia
9. CSL Behring Medical Product Donation Helps Meet Critical Need for Ongoing Cholera Relief Effort in Haiti
10. CSL Behring Announces Completion of National Marketing Authorizations of Berinert® After MRP in 23 European Countries
11. CSL Behring Announces FDA Approval of Berinert(R), First and Only Therapy Approved for the Treatment of Acute Abdominal and Facial Attacks of Hereditary Angioedema in U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014 Valeant Pharmaceuticals International, Inc. (NYSE: ... the company,s Bridgewater, New Jersey ... and Drug Administration (FDA) relating to an inspection in ... Sculptra Aesthetic injectable, which was divested to Galderma S.A. ... of Valeant,s contract manufacturers (rather than Valeant,s own internal ...
(Date:9/30/2014)... 2014 The Eastern European medical device industry ... as well as new medical-device manufacturers are constantly trying ... at ways to reduce the cost incurred for placing ... of the effective means to achieve this target. This ... Eastern European and provides profiles of key distributors in ...
(Date:9/30/2014)...   Decision Resources Group finds that through ... kidney disease non-dialysis (CKD-ND) patients are not highly ... addition, one-year persistency is similar between Amgen,s Aranesp ... findings from the report entitled Treatment ... Agents in Late Stage Chronic Kidney Disease and ...
Breaking Medicine Technology:Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2Medical Technologies Distributor Profiles in Eastern Europe 2Medical Technologies Distributor Profiles in Eastern Europe 3Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 2Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 3
... 2011 Cumberland Pharmaceuticals Inc. (Nasdaq: ... hospital acute care and gastroenterology markets, today announced that ... UBS Global Specialty Pharmaceuticals Conference in London on Wednesday, ... The presentation will be simultaneously webcast and can be ...
... 11, 2011 Doctors in Germany are among the ... States with the REVIVE™ SE, a new self-expanding blood ... clots and restore blood flow to the brain in ... Shurtleff, Inc., a global neuroscience and neurovascular company, received ...
Cached Medicine Technology:Doctors in Germany Among First to Use New Self-Expanding Clot Removal Device for Ischemic Stroke 2Doctors in Germany Among First to Use New Self-Expanding Clot Removal Device for Ischemic Stroke 3
(Date:9/30/2014)... 30, 2014 A new study ... studied the impact of stress on metabolism after eating a ... fries from a fast food restaurant, about 930 calories and ... for 20 minutes every hour for 7 hours, conducting the ... women who had experienced a stressful event in their lives ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Dynamic ... have hampered growth in the Bread Production industry ... caused consumers to moderate their consumption of a ... for premium varieties shrunk the market for white ... operators proactively responded by introducing more nutritious products ...
(Date:9/30/2014)... Integrated Medicine Alliance , Monmouth County’s ... medical specialty practice through a unique partnership with an ... located within the company’s Shrewsbury location and will be ... of American Heart Center, P.C., a highly regarded practice ... Integrated Medicine Alliance patients top notch cardiovascular care without ...
(Date:9/30/2014)... (FQHCs) granted new patient appointments to Medicaid beneficiaries ... primary care practices (non-FQHCs), in addition to charging ... new 10-state University of Pennsylvania study published this ... data from a previous "secret shopper" study conducted ... FQHCs community health clinics that receive federal ...
(Date:9/30/2014)... 30, 2014 Research by UC Irvine immunologists reveals ... light on a vital process that determines how the ... online version of Nature Immunology , neurology professor ... Institute for Immunology colleagues describe a critical mechanism underlying ... the bloodstream. , A T cell is a type ...
Breaking Medicine News(10 mins):Health News:NutriGold Urges Every Woman To Read a Recent Study About Diet and Stress 2Health News:NutriGold Urges Every Woman To Read a Recent Study About Diet and Stress 3Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Integrated Medicine Alliance Announces New Cardiology Practice 2Health News:Medicaid and Uninsured patients obtain new patient appointments most easily at FQHCs 2Health News:UCI study uncovers important process for immune system development 2
... April 27 Estill Medical Technologies, Inc., the industry ... announces the expansion of its Thermal Angel sales and ... mortality by quickly controlling core body temperature and infection ... administration. In emergency medicine, the golden hour refers to ...
... Members to Help Raise Obesity on the Nation,s Public ... health associations and obesity experts joined the S ... P revent (STOP) Obesity Alliance today as the organization ... grappling with the high costs of weight-related health conditions ...
... illnesses in which the immune system creates autoantibodies to ... non-profit Autoimmunity Research Foundation (ARF) explain that the antibodies ... human genes and gene products by hidden bacteria. , ... bacteria capable of causing human disease, But DNA discoveries ...
... Pharmaceuticals, a division of Wyeth (NYSE: ... has granted marketing authorization for CONBRIZA(TM) (bazedoxifene), a ... of postmenopausal osteoporosis in women at increased risk ... risk treatment guidelines and assessment tool for calculating ...
... Study shows those who respond to lapatinib survive longer, , , ... be used to treat aggressive inflammatory breast cancer, suggest the ... cancer accounts for up to 6 percent of all invasive ... to the researchers. Symptoms include rapid onset of swelling, ...
... to mirror Mandela,s values NEW YORK, April 27 46664 ... the world to support the creation of an official ... Mr. Mandela,s birthday. This celebration of Nelson Mandela,s life will ... recognize their individual power to make an imprint and help ...
Cached Medicine News:Health News:Thermal Angel Supports Infection Control During the Golden Hour 2Health News:As Health Reform Takes Shape, Leading Medical and Public Health Organizations Join Effort to Keep Obesity Front and Center 2Health News:As Health Reform Takes Shape, Leading Medical and Public Health Organizations Join Effort to Keep Obesity Front and Center 3Health News:As Health Reform Takes Shape, Leading Medical and Public Health Organizations Join Effort to Keep Obesity Front and Center 4Health News:'Autoantibodies' may be created in response to bacterial DNA 2Health News:Wyeth's CONBRIZA Approved in the European Union for Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture 2Health News:Wyeth's CONBRIZA Approved in the European Union for Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture 3Health News:Wyeth's CONBRIZA Approved in the European Union for Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture 4Health News:Drug May Help Against Inflammatory Breast Cancer 2Health News:46664 and the Nelson Mandela Foundation Call for Establishment of Global 'Mandela Day' 2Health News:46664 and the Nelson Mandela Foundation Call for Establishment of Global 'Mandela Day' 3Health News:46664 and the Nelson Mandela Foundation Call for Establishment of Global 'Mandela Day' 4Health News:46664 and the Nelson Mandela Foundation Call for Establishment of Global 'Mandela Day' 5
For universal arthroscopic meniscal repair/suture. Uses double-armed, single-throw sutures....
... Great Toe Implant (KGTI) system offers the ... the first MPJ. The implant system is ... motion. , ,The KGTI is the most ... joint (MPJ) on the market today. The ...
... Intraoperative Electrodes share similar characteristics ... main difference is that all ... numbered to assist you intraoperatively. ... designed for use with either ...
... full field digital mammography system signals ... in the world of mammography. This ... the latest advances in digital imaging ... to bring you the total solution ...
Medicine Products: